Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib

Abstract

Background

Autologous hematopoietic stem cell transplantation (AHSCT) remains the standard of care for younger patients with multiple myeloma (MM). Currently, high-dose melphalan (HDM) is recommended as conditioning regimen before AHSCT. Preclinical data suggest that combining bortezomib and melphalan has synergistic effect against multiple myeloma cells. Bortezomib and HDM (Bor-HDM) combination as conditioning regimen has been investigated by many other investigators.

Objective

In this retrospective study, we aimed to compare transplant-related toxicities and hematologic recovery of HDM and Bor-HDM conditioning regimens.

Method

We retrospectively evaluated hematologic recovery and toxicity profile in patients with MM who received AHSCT with either HDM (n = 114) or Bor-HDM (n = 53) conditioning regimen.

Results

Nonhematologic toxicities were comparable between HDM and Bor-HDM conditioning regimen, except mucositis and diarrhea being more frequent in the Bor-HDM group. Neutrophil and platelet engraftment time and duration of hospital stay were significantly shorter for HDM regimen.

Conclusions

In this retrospective analysis, we observed engraftment kinetics and duration of hospitalization were significantly worse in Bor-HDM conditioning regimen with manageable toxicities. Randomized studies are needed to further compare Bor- HDM regimen to HDM in terms of response rates, toxicities, and transplant-related mortality.

Keywords

Multiple myeloma bortezomib autologous stem cell transplantation conditioning regimen melphalan

Get full access to this article

View all access options for this article.

References

Kumar

Rajkumar

Dispenzieri

et al.

Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–2520.

Mey UJ, Leitner C, Driessen C, et al. Improved survival of older patients with multiple myeloma in the era of novel agents. Hematol Oncol 2015; 34: 217–223.

Attal

Harousseau

Stoppa

et al.

A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91–97.

Child

Morgan

Davies

et al.

High-dose chemotherapy with stem cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.

Shah

Thall

Fox

et al.

Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. Leukemia 2015; 29: 1945–1948.

Lahuerta

Mateos

Martínez-López

et al.

for the GEM (Grupo Español de MM) and PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatía Maligna) Cooperative Study Groups. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematologica 2010; 95: 1913–1920.

Mark

Reid

Niesvizky

et al.

A Phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 2013; 19: 831–837.

Qazilbash

Saliba

Nieto

et al.

Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant 2008; 14: 1401–1407.

Sharma

Khan

Thall

et al.

A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 2012; 118: 2507–2515.

10.

Ma MH, Yang HH, Parker K, et al. The proteosome inhibitör PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136–1144.

11.

Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteosome inhibitör PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377–2380.

12.

Miyamoto

Yoshimoto

Kamimura

et al.

Combination of high dose melphalan and bortezomib as a conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma. Int J Hematol 2013; 98: 337–345.

13.

Huang

et al.

High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy. Leuk Lymphoma 2012; 53: 2507–2510.

14.

Roussel

Moreau

Huynh

et al.

for the Intergroupe Francophone du Myélome (IFM). Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: A phase 2 study of the Intergroupe Francophone du Myélome (IFM). Blood 2010; 115: 32–37.

15.

Lee

Kim

Park

et al.

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma. Korean J Hematol 2010; 45: 183–187.

16.

Lonial

Kaufman

Tighiouart

et al.

A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: A dose- and schedule-finding study. Clin Cancer Res 2010; 16: 5079–5086.

17.

Takezako

Sekiqucki

Nagata

et al.

Bortezomib, dexamethasone, and high-dose melphalan as conditioning for stem cell transplantation in young Japanese multiple myeloma patients: A pilot study. Indian J Hematol Blood Transfus 2013; 29: 147–151.

18.

Thompson

Prince

Seymour

et al.

Bortezomib added to high-dose melphalan as pretransplant conditioning is safe in patients with heavily pre-treated multiple myeloma. Bone Marrow Transplant 2011; 46: 764–765.

19.

Gimsing

Hjertner

Abildgaard

et al.

Salvage bortezomib-dexamethasone and high dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase 2 trial. Bone Marrow Transplant 2015; 50: 1306–1311.

20.

Doo

Thompson

Prince

et al.

Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma. Leuk Lymphoma 2013; 54: 1465–1472.

21.

Nishihori

Alekshun

Shain

et al.

Bortezomib salvage followed by a phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Br J Haematol 2012; 157: 553–563.

22.

Blade

Samson

Reece

et al.

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–1123.

23.

Patriarca

Sperotto

Fili

et al.

Early chemosensitivity to VAD regimen predicts a favorable outcome after autologous stem cell transplantation in multiple myeloma. Haematologica 2002; 87: 779–781.

24.

Hari

Pasquini

Vesole

. Cure of multiple myeloma-more hype, less reality. Bone Marrow Transplant 2006; 37: 1–18.

25.

Wang

Delasalle

Feng

et al.

CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant 2010; 45: 498–504.

26.

Vij

Kumar

Zhang

et al.

Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. Biol Blood Marrow Transplant 2015; 21: 335–341.

27.

Kumar

Mahmood

Lacy

et al.

Impact of early relapse after auto-SCT for multiple myeloma. Bone Marrow Transplant 2008; 42: 413–420.

28.

Jimenez-Zepeda

Reece

Trudel

et al.

Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents. Bone Marrow Transplant 2015; 50: 204–208.

29.

Moreau

Facon

Attal

et al.

Comparison of 200 mg/m² melphalan and 8 Gy total body irradiation plus 140 mg/m² melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731–735.

30.

Parmar

Bookout

Shapiro

et al.

Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma. Bone Marrow Transplantation 2014; 49: 761–766.

31.

Miyakoshi

Kami

Yuji

et al.

Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory mutiple myeloma. Blood 2006; 107: 3492–3494.

32.

Gotoh

Ohyashiki

Oshimi

et al.

Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: A questionnaire-based report from the “lung injury by bortezomib” joint committee of Japanese Society of Hematology and the Japanese Society of Clinical Hematology. Int J Hematol 2006; 84: 406–412.

33.

Boyer

Batra

Ascensao

et al.

Severe pulmonary complication after bortezomib treatment for multiple myeloma. Blood 2006; 108: 1113–1113.

34.

Sugita

Ohwada

Nagao

et al.

Early-onset severe diffuse alveolar hemorrhage after bortezomib administration suggestive of pulmonary involvement of myeloma cells. J Clin Exp Hematop 2015; 55: 163–165.